Lose weight & keep it off for adults and children aged ≥12 years with obesity, or some adults with overweight and weight-related medical problems.

8 hours ago · Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply improving this year, and brushed off fears of the company falling behind Eli Lilly & Co. Details about its next …

Wegovy ® is the only GLP-1 RA proven to sustain ~15% mean weight loss at 2 years

Wegovy (semaglutide) injection 2.4 mg is indicated for chronic weight management for adults with obesity and to reduce the risk of major adverse cardiovascular events in adults with obesity or …

Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest …

Jan 17, 2025 · In the phase 3b STEP UP study, an experimental 7.2-mg semaglutide dose helped patients lose more weight on average at 72 weeks compared to placebo or semaglutide 2.4 …

Jan 17, 2025 · Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli...

Jan 20, 2025 · Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy …

May 14, 2024 · Novo Nordisk ’s blockbuster GLP-1 analog Wegovy (semaglutide) can maintain meaningful weight loss for up to four years and improve cardiovascular health regardless of …

May 23, 2023 · In the study, patients who received a 50 mg daily dose of the treatment lost an average of 15.1% of their weight over 68 weeks, compared with a 2.4% average weight loss …